Search clinical trials for: Glatiramer Acetate (GA) 40 mg

Total 1026 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Relapse-Remitting Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Tolerability of Glatiramer Acetate (GLACIER)

Relapsing-Remitting Multiple Sclerosis

United States
Teva Pharmaceutical Industries, Ltd.

Completed

Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Belgium, France, Germany, Israel, Italy, United Kingdom
Mapi Pharma Ltd.

Active, not recruiting

Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS

Multiple Sclerosis

Israel
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo (GALA)

Relapsing Remitting Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Poland, Romania, Russian Federation, South Africa, Ukraine, United Kingdom
Teva Neuroscience, Inc.

Completed

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients (ENCORE)

Multiple Sclerosis
EMD Serono

Terminated

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

Relapsing Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, Italy, Mexico, Russian Federation, South Africa, Spain, Turkey, Hungary, Poland, Ukraine, Finland, United Kingdom, Greece, Serbia
Synthon BV

Completed

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom
Teva Neuroscience, Inc.

Completed

A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®

Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome (PreCISe)

Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Relapsing Remitting Multiple Sclerosis
Fred Lublin
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

Relapsing Remitting Multiple Sclerosis

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline

Relapse Remitting Multiple Sclerosis
Sanofi

Completed

FOCUS Fatigue Outcome in Copaxone USers

Multiple Sclerosis

Czech Republic
Federal University of São Paulo

Unknown

Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation

Diabetic Retinopathy

Brazil
Sheba Medical Center

Unknown

Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate

Multiple Sclerosis

Israel
Amphia Hospital
Sanofi; TEVA Pharmachemie

Unknown

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) (OCTIMS)

Multiple Sclerosis

Netherlands
Kaplan Medical Center

Unknown

Copaxone in Age Related Macular Degeneration

Macular Degeneration

Israel
Tel-Aviv Sourasky Medical Center
Teva Branded Pharmaceutical Products R&D, Inc.; Medtronic - MITG

Unknown

A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease (Cop1CD)

Crohns Disease

Israel
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Relapsing-Remitting Multiple Sclerosis

United States
Sanofi

Completed

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, United Kingdom, Austria, Italy
University of Kansas Medical Center

Active, not recruiting

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Basal Cell Carcinoma | Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Sheba Medical Center

Unknown

An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome

Rett Syndrome

Israel
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety of New Formulation of Glatiramer Acetate (Song)

Relapsing Remitting Multiple Sclerosis
University of California, San Francisco
National Multiple Sclerosis Society; Teva Neuroscience, Inc.

Completed

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

Multiple Sclerosis

United States
Teva Takeda Pharma Ltd.

Completed

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Multiple Sclerosis

Japan
Genencell Co. Ltd.

Recruiting

Efficacy and Safety of ES16001 in Patients With COVID-19

COVID-19

Korea, Republic of
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer

Breast Cancer | Hot Flashes
Novartis Pharmaceuticals

Completed

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (EPOC)

Relapsing Remitting Multiple Sclerosis

Russian Federation
University at Buffalo
Teva Neuroscience, Inc.

Completed

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

Multiple Sclerosis

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Advanced Solid Tumor

United States
Singapore Eye Research Institute

Unknown

Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure

Glaucoma, Angle-closure, Primary, Acute

Singapore
Grupo Español de Tumores Huérfanos e Infrecuentes
Astellas Pharma Inc; Apices Soluciones S.L.

Completed

Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study (GREKO III)

Ovarian Cancer

Spain
Neurognostics

Terminated

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Healthy

United States
Repros Therapeutics Inc.

Completed

Extension of Study ZPV-200

Uterine Fibroids

United States
Sandoz

Completed

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (Mylight)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, Czechia, Australia, Austria, France, Germany, Hungary, Israel, Japan, Latvia, Lithuania, Poland, Portugal, Slovakia, Spain
University of Medicine and Dentistry of New Jersey

Completed

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI (BECOME)

Multiple Sclerosis

United States
Zhongda Hospital
Sun Yat-sen University; Jiangsu Cancer Institute & Hospital; Zhejiang University and other collaborators

Not yet recruiting

A Real World Study of Regogfinib in HCC

Hepatocellular Carcinoma
Vigonvita Life Sciences

Completed

Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Healthy Subjects

China
Biocad

Completed

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

Rheumatoid Arthritis

Germany, United Kingdom
AstraZeneca

Completed

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Reflux

Netherlands, Belgium
University of Bologna
Ipsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaborators

Unknown

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

Non Small Cell Lung Cancer

Italy
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.

Multiple Sclerosis
UroGen Pharma Ltd.

Completed

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Neoplasms | Urologic Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms

India
Institute of Cancer Research, United Kingdom
AstraZeneca; Astellas Pharma Inc; Prostate Cancer UK

Terminated

Combination Study of AZD5069 and Enzalutamide. (ACE)

Metastatic Castration Resistant Prostate Cancer

United Kingdom, Switzerland
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

Healthy

Germany
Johns Hopkins University

Withdrawn

High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis (HiCy)

Relapsing Remitting Multiple Sclerosis

United States

Search clinical trials for: Glatiramer Acetate (GA) 40 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations